Trial Profile

Observational Cohort Study to Evaluate Safety and Efficacy of Pradaxa (Dabigatran Etexilate) in Patients With Moderate Renal Impairment (Creatinine Clearance 30-50 ml/Min) Undergoing Elective Total Hip Replacement Surgery or Total Knee Replacement Surgery.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 09 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dabigatran etexilate (Primary)
Indications Deep vein thrombosis; Pulmonary embolism; Thromboembolism; Venous thromboembolism
Focus Adverse reactions; Therapeutic Use
Sponsors Boehringer Ingelheim Pharmaceuticals

23 Jul 2014 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
25 Jun 2014 Planned End Date changed from 1 Aug 2014 to 1 Jul 2014, as per ClinicalTrials.gov record.
25 Jun 2014 Planned primary completion date changed from 1 Aug 2014 to 1 Jul 2014, as per ClinicalTrials.gov record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com